NEW YORK (GenomeWeb) –  Biocept reported after the close of the market Thursday that its third quarter 2017 revenues rose around 10 percent year over year.

The liquid biopsy assay developer reported total revenues of $1.1 million for the three months ended Sept. 30, up from $1 million in the same period last year.

Of the $1.1 million of revenues recognized during Q3 2017, $900,000 was revenues recognized on an accrual basis and $102,000 reflected the receipt of cash. Biocept converted from cash-based to accrual-based reporting in Q1 of this year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.